Literature DB >> 22212399

Pulmonary function vascular index predicts prognosis in idiopathic interstitial pneumonia.

Tamera J Corte1, Stephen J Wort, Peter S MacDonald, Anthony Edey, David M Hansell, Elisabetta Renzoni, Toby M Maher, Andrew G Nicholson, Steven Bandula, Paul Bresser, Athol U Wells.   

Abstract

BACKGROUND AND
OBJECTIVE: Pulmonary hypertension (PH) is associated with increased mortality in fibrotic idiopathic interstitial pneumonia (IIP). We hypothesize that baseline K(CO) (diffusing capacity of carbon monoxide/alveolar volume) and 6-month decline in K(CO) reflect PH, thus predicting mortality in IIP.
METHODS: All IIP referrals (2004-2007) were identified (n = 269). 192 had pulmonary function at 6 months. Fifty-two (27%) died during follow-up (median 22.5 months). Outcome was evaluated for early (1 year from 6-month pulmonary function) and overall mortality. A vascular index best predicting mortality was identified (using baseline and 6-month decline in K(CO) ) and evaluated against PH at echocardiography.
RESULTS: Baseline and 6-month decline in K(CO) were associated with early and overall mortality. A positive vascular index (baseline K(CO) % ≤ 50% and/or ≥15% decline in K(CO) at 6 months; n = 40) was strongly predictive of early and overall mortality. Neither a diagnosis of idiopathic pulmonary fibrosis nor PH predicted early death when incorporated into this model. In patients without baseline PH, with follow-up echocardiography (n = 60), a positive vascular index was associated with PH at follow-up.
CONCLUSIONS: A vascular index comprised of baseline and 6-month decline in K(CO) strongly predicted increased mortality and development of PH on echocardiography. In, K(CO) may be an important marker for pulmonary vascular disease and its associated mortality.
© 2011 The Authors. Respirology © 2011 Asian Pacific Society of Respirology.

Entities:  

Mesh:

Year:  2012        PMID: 22212399     DOI: 10.1111/j.1440-1843.2011.02121.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  5 in total

Review 1.  IPF clinical trial design and endpoints.

Authors:  Steven D Nathan; Keith C Meyer
Journal:  Curr Opin Pulm Med       Date:  2014-09       Impact factor: 3.155

Review 2.  Molecular biomarkers in interstitial lung diseases.

Authors:  Angelo De Lauretis; Elisabetta A Renzoni
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

3.  Circulating biomarkers of interstitial lung disease in systemic sclerosis.

Authors:  Harpreet K Lota; Elisabetta A Renzoni
Journal:  Int J Rheumatol       Date:  2012-09-03

4.  Different KCO and VA combinations exist for the same DLCO value in patients with diffuse parenchymal lung diseases.

Authors:  Jean Pastre; Laurent Plantier; Carole Planes; Raphaël Borie; Hilario Nunes; Christophe Delclaux; Dominique Israël-Biet
Journal:  BMC Pulm Med       Date:  2015-09-03       Impact factor: 3.317

5.  Prognosis of nonspecific interstitial pneumonia correlates with perivascular CD4+ T lymphocyte infiltration of the lung.

Authors:  Ling Qin; WenZe Wang; HongRui Liu; Yi Xiao; MingWei Qin; WenJie Zheng; JuHong Shi
Journal:  BMC Pulm Med       Date:  2015-10-24       Impact factor: 3.317

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.